An Inflammatory Phenotype in Early Scleroderma: Tocilizumab or Mycophenolate First?
A newly diagnosed scleroderma patient's rising skin score and elevated inflammatory markers match a landmark trial's own inclusion criteria almost exactly — the disagreement is whether that match should override the broader, older standard of care.
A.N., a 39-year-old second-grade teacher, first noticed her fingers stiffening into fists she had to consciously unclench each morning before she could tie her students' shoes for them — an early sign of the diffuse cutaneous systemic sclerosis diagnosed fourteen months ago. Her skin disease hasn't settled the way her rheumatologist hoped: her modified Rodnan skin score has continued climbing rather than plateauing, and her C-reactive protein has stayed persistently elevated across three separate visits, a pattern more consistent with ongoing active disease than a slow burn toward stability. A baseline HRCT obtained as part of routine ILD screening showed ground-glass opacity with early reticulation at the lung bases — interstitial lung disease already present, though her FVC at 81% predicted is not yet dramatically reduced. She has no other medical history of note, and this is the first medication being considered specifically for either her skin or her lungs.
Mycophenolate mofetil has been the default first agent in systemic sclerosis-ILD since Scleroderma Lung Study II found it comparable to cyclophosphamide with meaningfully better tolerability, and it remains the broadest, best-established starting point for most patients. Tocilizumab is a narrower, more specific option: the focuSSced trial that earned its FDA approval for SSc-ILD enrolled early diffuse disease with elevated acute-phase reactants — precisely A.N.'s own profile — and among the two thirds of that trial who had ILD at baseline, tocilizumab-treated patients lost essentially no FVC over 48 weeks (a mean change of −14mL) against a −255mL decline on placebo. Two things qualify that number rather than undo it. It comes from a post-hoc subgroup analysis, not a prespecified one. And the trial's own primary endpoint, skin thickening by modified Rodnan score, did not separate from placebo — which is why the FDA's own approval language cautions that the size of the lung effect should be read carefully, and which is also the detail that keeps this from being a simple substitution: whatever tocilizumab does for her, the evidence says clearly it is not a skin drug, even though her skin is what has been climbing.
Which drug, and which problem
Start mycophenolate. Scleroderma Lung Study II (Tashkin et al.) found it comparable to cyclophosphamide with meaningfully better tolerability, it's the broadest first-line standard in SSc-ILD, and it has some real activity against both her skin and lung disease — a genuine advantage when both are active at once.
You're right that mycophenolate has the broader evidence base overall. But focuSSced specifically enrolled early diffuse disease with elevated acute-phase reactants, and A.N.'s profile — rising mRSS, persistently high CRP, fourteen months in — sits inside exactly that population; in its ILD subgroup tocilizumab held FVC essentially flat (−14mL) against a −255mL placebo decline at 48 weeks. Post-hoc, granted, but she matches the enrolment profile on every axis the trial stratified.
Calling mycophenolate the “broader” choice treats her as a generic SSc-ILD patient when the actual evidence available is about a patient who looks specifically like her.
One caution either way: focuSSced's own primary endpoint, modified Rodnan skin score, didn't separate from placebo. Whichever drug is chosen for her lungs, her rising skin score — the finding that actually brought her in — needs its own honest plan, not an assumption that a lung-protective drug will also settle it.
Agreed: start tocilizumab given how closely her profile matches focuSSced's own benefiting subgroup, with FVC rechecked at 12 and 24 weeks.
Not agreed: whether mycophenolate should be added now for her skin disease specifically, given tocilizumab's own null skin result — the rheumatologist wants to add it today; the pulmonologist would rather isolate tocilizumab's lung effect for one clean interval before layering a second immunosuppressant.